We are investigating whether adding the drug inavolisib to standard treatments helps patients with HER2-positive, HR-positive, PIK3CA mutant early breast cancer achieve better treatment responses. This study compares the new combination therapy to standard therapy alone.
Health conditions and diseases that the clinical trial is designed to study and treat.
Breast cancer is a type of cancer that forms in the cells of the breasts, and it can affect both men and women. It often presents with symptoms such as a lump in the breast, changes in breast shape or size, and unusual discharge from the nipple.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Don't worry if you don't know the medicines tested in the trial. There is a chance you have heard about the similar medicines. Check the list below to see if you are familiar with any of them.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.
